Your browser doesn't support javascript.
loading
An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers.
Blein, Sophie; Bardel, Claire; Danjean, Vincent; McGuffog, Lesley; Healey, Sue; Barrowdale, Daniel; Lee, Andrew; Dennis, Joe; Kuchenbaecker, Karoline B; Soucy, Penny; Terry, Mary Beth; Chung, Wendy K; Goldgar, David E; Buys, Saundra S; Janavicius, Ramunas; Tihomirova, Laima; Tung, Nadine; Dorfling, Cecilia M; van Rensburg, Elizabeth J; Neuhausen, Susan L; Ding, Yuan Chun; Gerdes, Anne-Marie; Ejlertsen, Bent; Nielsen, Finn C; Hansen, Thomas Vo; Osorio, Ana; Benitez, Javier; Conejero, Raquel Andrés; Segota, Ena; Weitzel, Jeffrey N; Thelander, Margo; Peterlongo, Paolo; Radice, Paolo; Pensotti, Valeria; Dolcetti, Riccardo; Bonanni, Bernardo; Peissel, Bernard; Zaffaroni, Daniela; Scuvera, Giulietta; Manoukian, Siranoush; Varesco, Liliana; Capone, Gabriele L; Papi, Laura; Ottini, Laura; Yannoukakos, Drakoulis; Konstantopoulou, Irene; Garber, Judy; Hamann, Ute; Donaldson, Alan; Brady, Angela.
Afiliação
  • Blein S; INSERM U1052, CNRS UMR5286, Université Lyon 1, Centre de Recherche en Cancérologie de Lyon, Lyon, France. sophie.blein@gmail.com.
  • Bardel C; Université de Lyon, 69000, Lyon, France. sophie.blein@gmail.com.
  • Danjean V; Université Lyon 1, 69100, Villeurbanne, France. sophie.blein@gmail.com.
  • McGuffog L; Université de Lyon, 69000, Lyon, France. claire.bardel@univ-lyon1.fr.
  • Healey S; Université Lyon 1, 69100, Villeurbanne, France. claire.bardel@univ-lyon1.fr.
  • Barrowdale D; UMR CNRS 5558, Laboratoire de Biométrie et Biologie Évolutive (LBBE), "Biométrie et Biologie Évolutive", Université Claude Bernard Lyon 1, Bâtiment Grégor Mendel, 43 boulevard du 11 novembre 1918, 69622, Villeurbanne, cedex, France. claire.bardel@univ-lyon1.fr.
  • Lee A; Université Grenoble Alpes, UMR 5217, Laboratoire d'Informatique de Grenoble (LIG), équipe-projet Multi-programmation et Ordonnancement sur ressources pour les Applications Interactives de Simulation (MOAIS), 38041, Grenoble, France. vincent.danjean@ens-lyon.org.
  • Dennis J; INRIA Rhône-Alpes, équipe-projet MOAIS, 38334, Saint Ismier, Cedex, France. vincent.danjean@ens-lyon.org.
  • Kuchenbaecker KB; Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK. lesley@srl.cam.ac.uk.
  • Soucy P; Department of Genetics and Computational Biology, QIMR Berghofer, Brisbane, Australia. sue.healey@qimrberghofer.edu.au.
  • Terry MB; Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK. daniel@srl.cam.ac.uk.
  • Chung WK; Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK. andrewl@srl.cam.ac.uk.
  • Goldgar DE; Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK. jgd29@cam.ac.uk.
  • Buys SS; Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK. karoline@srl.cam.ac.uk.
  • Janavicius R; Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY, USA. mt146@cumc.columbia.edu.
  • Tihomirova L; Department of Pediatrics, Columbia University College of Physicians and Surgeons, New York, NY, USA. wkc15@columbia.edu.
  • Tung N; Department of Medicine, Columbia University College of Physicians and Surgeons, New York, NY, USA. wkc15@columbia.edu.
  • Dorfling CM; Department of Dermatology, University of Utah School of Medicine, Salt Lake City, UT, USA. david.goldgar@hsc.utah.edu.
  • van Rensburg EJ; Department of Internal Medicine, Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, UT, USA. saundra.buys@hci.utah.edu.
  • Ding YC; Hematology, Oncology and Transfusion Medicine Center, Vilnius University Hospital Santariskiu Clinics, Vilnius, Lithuania. ramunas.janavicius@santa.lt.
  • Gerdes AM; Department of Molecular and Regenerative Medicine, Centre for Innovative Medicine, State Research Institute, Vilnius, Lithuania. ramunas.janavicius@santa.lt.
  • Ejlertsen B; Latvian Biomedical Research and Study Centre, Ratsupites iela 1, Riga, LV-1067, Latvia. laima@biomed.lu.lv.
  • Nielsen FC; Division of Hematology Oncology, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Shapiro 9, Boston, MA, 02215-5400, USA. ntung@bidmc.harvard.edu.
  • Hansen TV; Department of Genetics, University of Pretoria, Private Bag X20, Hatfield, 0028, Pretoria, South Africa. celmari.dorfling@up.ac.za.
  • Osorio A; Department of Genetics, University of Pretoria, Private Bag X20, Hatfield, 0028, Pretoria, South Africa. lizette.vanrensburg@up.ac.za.
  • Benitez J; Department of Population Sciences, Beckman Research Institute, City of Hope, 1500 East Duarte Road, Duarte, CA, 91010, USA. sneuhausen@coh.org.
  • Conejero RA; Department of Population Sciences, Beckman Research Institute, City of Hope, 1500 East Duarte Road, Duarte, CA, 91010, USA. ycding@coh.org.
  • Segota E; Department of Clinical Genetics, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark. anne-marie.gerdes@regionh.dk.
  • Weitzel JN; Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark. bent.ejlertsen@regionh.dk.
  • Thelander M; Center for Genomic Medicine, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark. fcn@rh.dk.
  • Peterlongo P; Center for Genomic Medicine, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark. tvoh@rh.dk.
  • Radice P; Human Genetics Group, Spanish National Cancer Research Center (CNIO), Madrid, Spain. aosorio@cnio.es.
  • Pensotti V; Center for Biomedical Network Research on Rare Diseases (CIBERER), Madrid, Spain. aosorio@cnio.es.
  • Dolcetti R; Human Genetics Group, Spanish National Cancer Research Center (CNIO), Madrid, Spain. jbenitez@cnio.es.
  • Bonanni B; Center for Biomedical Network Research on Rare Diseases (CIBERER), Madrid, Spain. jbenitez@cnio.es.
  • Peissel B; Medical Oncology Service, Hospital Clínico Universitario Lozano Blesa, Avenida San Juan Bosco, 15, 50009, Zaragoza, Spain. andresraquel@hotmail.com.
  • Zaffaroni D; Holy Cross Hospital, Michael and Dianne Bienes Comprehensive Cancer Center, Fort Lauderdale, FL, USA. zdenka.segota@holy-cross.com.
  • Scuvera G; Clinical Cancer Genetics Community Research Network, City of Hope, 1500 East Duarte Road, Duarte, CA, 91010, USA. zdenka.segota@holy-cross.com.
  • Manoukian S; Division of Clinical Cancer Genetics, City of Hope (for the Clinical Cancer Genetics Community Research Network), City of Hope, 1500 East Duarte Road, Duarte, CA, 91010, USA. jweitzel@coh.org.
  • Varesco L; John Muir Medical Center, Walnut Creek, CA, USA; c/o Clinical Cancer Genetics Community Research Network, City of Hope, 1500 East Duarte Road, Duarte, CA, 91010, USA. margo.thelander@johnmuirhealth.com.
  • Capone GL; Istituto FIRC di Oncologia Molecolare (IFOM), Via Adamello 16, 20139, Milan, Italy. paolo.peterlongo@ifom.eu.
  • Papi L; Unit of Molecular Bases of Genetic Risk and Genetic Testing, Department of Preventive and Predictive Medicine, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Istituto Nazionale dei Tumori (INT), Via Venezian 1, 20133, Milan, Italy. paolo.radice@istitutotumori.mi.it.
  • Ottini L; Division of Clinical Cancer Genetics, City of Hope (for the Clinical Cancer Genetics Community Research Network), City of Hope, 1500 East Duarte Road, Duarte, CA, 91010, USA. valeria.pensotti@ifom.eu.
  • Yannoukakos D; Cogentech Cancer Genetic Test Laboratory, Via Adamello 16, 20139, Milan, Italy. valeria.pensotti@ifom.eu.
  • Konstantopoulou I; Cancer Bioimmunotherapy Unit, Centro di Riferimento Oncologico (CRO), Via Franco Gallini 2, 33081, Aviano, Italy. rdolcetti@cro.it.
  • Garber J; Division of Cancer Prevention and Genetics, Istituto Europeo di Oncologia, Via Ripamonti 435, 20141, Milan, Italy. bernardo.bonanni@ieo.it.
  • Hamann U; Unit of Medical Genetics, Department of Preventive and Predictive Medicine, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Istituto Nazionale dei Tumori (INT), Via Venezian 1, 20133, Milan, Italy. bernard.peissel@istitutotumori.mi.it.
  • Donaldson A; Unit of Medical Genetics, Department of Preventive and Predictive Medicine, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Istituto Nazionale dei Tumori (INT), Via Venezian 1, 20133, Milan, Italy. daniela.zaffaroni@istitutotumori.mi.it.
  • Brady A; Unit of Medical Genetics, Department of Preventive and Predictive Medicine, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Istituto Nazionale dei Tumori (INT), Via Venezian 1, 20133, Milan, Italy. giulietta.scuvera@istitutotumori.m.it.
Breast Cancer Res ; 17: 61, 2015 Apr 25.
Article em En | MEDLINE | ID: mdl-25925750
ABSTRACT

INTRODUCTION:

Individuals carrying pathogenic mutations in the BRCA1 and BRCA2 genes have a high lifetime risk of breast cancer. BRCA1 and BRCA2 are involved in DNA double-strand break repair, DNA alterations that can be caused by exposure to reactive oxygen species, a main source of which are mitochondria. Mitochondrial genome variations affect electron transport chain efficiency and reactive oxygen species production. Individuals with different mitochondrial haplogroups differ in their metabolism and sensitivity to oxidative stress. Variability in mitochondrial genetic background can alter reactive oxygen species production, leading to cancer risk. In the present study, we tested the hypothesis that mitochondrial haplogroups modify breast cancer risk in BRCA1/2 mutation carriers.

METHODS:

We genotyped 22,214 (11,421 affected, 10,793 unaffected) mutation carriers belonging to the Consortium of Investigators of Modifiers of BRCA1/2 for 129 mitochondrial polymorphisms using the iCOGS array. Haplogroup inference and association detection were performed using a phylogenetic approach. ALTree was applied to explore the reference mitochondrial evolutionary tree and detect subclades enriched in affected or unaffected individuals.

RESULTS:

We discovered that subclade T1a1 was depleted in affected BRCA2 mutation carriers compared with the rest of clade T (hazard ratio (HR) = 0.55; 95% confidence interval (CI), 0.34 to 0.88; P = 0.01). Compared with the most frequent haplogroup in the general population (that is, H and T clades), the T1a1 haplogroup has a HR of 0.62 (95% CI, 0.40 to 0.95; P = 0.03). We also identified three potential susceptibility loci, including G13708A/rs28359178, which has demonstrated an inverse association with familial breast cancer risk.

CONCLUSIONS:

This study illustrates how original approaches such as the phylogeny-based method we used can empower classical molecular epidemiological studies aimed at identifying association or risk modification effects.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Genes BRCA2 / Genes Mitocondriais / Heterozigoto / Mutação Tipo de estudo: Etiology_studies / Risk_factors_studies Limite: Female / Humans Idioma: En Revista: Breast Cancer Res Assunto da revista: NEOPLASIAS Ano de publicação: 2015 Tipo de documento: Article País de afiliação: França

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Genes BRCA2 / Genes Mitocondriais / Heterozigoto / Mutação Tipo de estudo: Etiology_studies / Risk_factors_studies Limite: Female / Humans Idioma: En Revista: Breast Cancer Res Assunto da revista: NEOPLASIAS Ano de publicação: 2015 Tipo de documento: Article País de afiliação: França